Anxiety Disorders
Anxiety disorders are the most common mental health conditions in the world, yet for primary anxiety (generalised anxiety, social anxiety, panic) the psychedelic evidence is surprisingly thin. The clear front-runner is LSD: MindMed’s MM120 met its Phase 2b endpoint in generalised anxiety disorder and is now in two Phase 3 trials. Most other psychedelic anxiety data comes from cancer and end-of-life distress, a different problem covered on our palliative page, or is measured as a side effect of treating depression.
How are psychedelics being studied for anxiety disorders? Anxiety disorders involve excessive, persistent fear or worry that interferes with daily life, and they often occur alongside depression. Much of the psychedelic research here focuses on anxiety linked to life-threatening illness, where psilocybin given in supervised sessions with support has eased anxiety and depression in small trials, sometimes with lasting effect. MDMA has been studied for social anxiety in autistic adults, and LSD for anxiety more broadly. The model is a small number of supported sessions rather than daily medication. The evidence is early and based on modest samples, and blinding is difficult, so questions remain about who benefits and how durable the effect is outside the trial setting. Blossom tracks the trials and papers behind anxiety research so you can follow the evidence.
Data updated
Key Insights
- 1
For primary anxiety disorders, the most advanced psychedelic is LSD: MindMed’s MM120 met its Phase 2b endpoint in generalised anxiety disorder (a single dose cut Hamilton Anxiety scores by 5 to 6 points more than placebo), earned FDA Breakthrough Therapy status, and is now in two Phase 3 trials reading out in 2026.
- 2
That headline comes with an asterisk: the two lower MM120 doses did not beat placebo, and because almost everyone on an active dose noticed perceptual effects (up to 100%, versus about 10% on placebo), blinding is hard, which the Phase 3 programme is explicitly designed to test.
- 3
Most "psychedelics for anxiety" evidence is actually about anxiety in life-threatening illness (cancer, palliative care), a distinct problem of existential distress that we cover on our palliative page, not generalised or social anxiety.
- 4
Psilocybin and MDMA for primary anxiety are early: psilocybin GAD trials are only now recruiting, and the main MDMA social-anxiety study is a 20-person open-label trial with no active placebo.
- 5
A recurring honesty problem is that anxiety improvements in these trials often track depression improvements (and disappear once depression is accounted for), and control groups improve substantially too, so independent anxiolytic efficacy is far less settled than the effect sizes suggest.
By the numbers
- 110
- Trials tracked
- 769
- Papers tracked
- 11,871
- Trial participants
as of June 2026
as of June 2026
as of June 2026
Questions & Answers
The questions readers most often ask about Anxiety Disorders, answered with the data Blossom tracks.
Which psychedelic is studied most for anxiety?
Psilocybin has the most evidence, especially for anxiety linked to life-threatening illness; MDMA has been studied for social anxiety in autistic adults. Blossom lists the trials.
Is psychedelic therapy for anxiety available now?
Largely only within clinical trials. Blossom tracks trial access and status.
What is Anxiety Disorders?
Anxiety disorders are a family of conditions, generalised anxiety disorder (GAD), social anxiety disorder, panic disorder and specific phobias, defined by excessive, persistent fear and worry that interferes with daily life. They are the most common mental disorders in the world, affecting roughly 301 million people[1]. They are also highly treatable for many people, and they overlap heavily with depression, which matters for how the psychedelic evidence below should be read.
This page is scoped to primary anxiety disorders. That distinction is important because the large majority of "psychedelics for anxiety" research is actually about anxiety and existential distress in people with life-threatening illness, mostly advanced cancer. That is a genuinely different clinical problem, and we cover it on our palliative and end-of-life distress page. Here the focus is on anxiety as the primary disorder, where, perhaps surprisingly given the volume of coverage, the rigorous evidence is still thin.
Current Treatments
Standard care for anxiety disorders is well established and works for many people: cognitive behavioural therapy (including exposure-based approaches) and SSRIs or SNRIs are first-line, with benzodiazepines used short-term despite dependence risk. The unmet need is real but narrower than in, say, treatment-resistant depression: a meaningful minority do not respond adequately, relapse is common, and side effects and the slow onset of antidepressants drive interest in alternatives.
That is the gap the psychedelic approaches are aiming at, and the pitch is a fast-acting, possibly single-dose treatment rather than daily medication. None of the compounds below is approved for any anxiety disorder. The most advanced, LSD for generalised anxiety, is still in Phase 3 testing, and the rest are earlier. So this is a field of promising early signals, not established treatments.
This report summarises what Blossom’s database shows about psychedelic treatments for anxiety disorders, and what it does not show. The short version is a useful corrective to the hype: despite anxiety being the most common mental health problem in the world, the rigorous evidence for psychedelics in primary anxiety disorders is thin, and it rests mostly on one compound. LSD, in the form of MindMed’s MM120, has a positive Phase 2b trial in generalised anxiety disorder and is in Phase 3. Almost everything else either belongs to a different problem (anxiety in life-threatening illness) or is early and uncontrolled.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a treatment recommendation. No psychedelic is approved for any anxiety disorder; the most advanced, LSD for generalised anxiety, is still in Phase 3 trials. Anxiety disorders are common and treatable with established therapies, and decisions about treatment belong with a qualified clinician.
Two scoping points matter a great deal here. First, Blossom tracks 772 papers and 110 trials under this topic, and those counts appear on the page, but the tag is unusually leaky: most of it is anxiety in the context of cancer and palliative care, or anxiety measured as a secondary outcome in depression, PTSD and OCD trials. The genuinely primary-anxiety core is small. Second, we deliberately scope this page to primary anxiety disorders (generalised anxiety, social anxiety, panic, phobia) and cover anxiety in life-threatening illness separately on our palliative page, because the latter is a distinct problem of existential distress. Read the counts as database coverage, not as a tally of anxiety-disorder treatments.
What anxiety disorders are, and why the bar is different
Anxiety disorders involve excessive, persistent fear and worry, and as a group they are the most common mental disorders worldwide, affecting around 301 million people[1]. Unlike treatment-resistant depression, they already have effective first-line treatments (CBT, SSRIs and SNRIs) that work for many people. That changes the bar: a new treatment has to improve on options that are genuinely useful, and the clearest unmet need is the minority who do not respond or who relapse. It is in that space that the psychedelic programmes are positioned.
LSD (MM120): the only advanced primary-anxiety programme
The single most important result on this page is from LSD. In a Phase 2b trial of 198 adults with generalised anxiety disorder, a single dose of MM120 reduced Hamilton Anxiety (HAM-A) scores by 5.0 points at 100 µg and 6.0 points at 200 µg more than placebo at four weeks[2], with benefit reported through twelve weeks from one dose. For a condition where treatments are taken daily, a durable single-dose effect would be a meaningful change.
That trial earned FDA Breakthrough Therapy designation and launched two Phase 3 trials, Voyage and Panorama, with readouts expected in 2026[3]. It is genuinely the furthest any psychedelic has advanced in a primary anxiety disorder, and it is why this page treats LSD, not the more famous psilocybin, as the front-runner here.
The dose and blinding question
The same Phase 2b data contain the main caveats. The two lower doses (25 µg and 50 µg) did not separate from placebo[2], so the effect is dose-dependent and concentrated at doses that produce a clear psychedelic experience. And that is the problem: almost everyone on an active therapeutic dose noticed perceptual effects, against about one in ten on placebo, which makes genuine blinding very hard. Participants who can tell they received the drug may improve partly because they expect to. The Panorama Phase 3 trial was designed in part to probe exactly this, which is an encouraging sign that the developers are taking the criticism seriously rather than ignoring it.
Psilocybin: strong in cancer distress, thin for generalised anxiety
Psilocybin is where the scoping really bites. Its most impressive anxiety results come from people with life-threatening illness. Landmark 2016 trials in cancer patients found that a single high dose produced substantial reductions in anxiety and depression that were sustained at six months[4], a finding replicated in a parallel trial[5] and reinforced by a 2025 placebo-controlled palliative-care trial reporting a large, durable reduction in state anxiety[6]. This is real and important, but it is about existential distress at the end of life, which we cover on our palliative page, not about generalised or social anxiety.
For primary anxiety disorders, psilocybin is early. Dedicated generalised-anxiety trials are only now recruiting, and the anxiety improvements seen in other populations often turn out to be downstream of depression: in veterans with treatment-resistant depression, anxiety scores fell by more than half but the change lost significance once depression improvement was accounted for[7]. There is a promising signal in OCD, an anxiety-spectrum condition, where a small randomised trial reported 73% responders and 40% remission[8], but the sample was just fifteen people. The honest summary is that psilocybin’s reputation in anxiety rests largely on cancer work that does not transfer automatically to primary anxiety.
MDMA for social anxiety: a large signal, a weak design
Social anxiety disorder is a natural target for MDMA, which reduces fear and increases social ease. The main recent study is an open-label, waitlist-controlled trial in 20 adults with social anxiety that reported a very large improvement (Hedges’ g of 2.8) with no serious adverse events[9], extending an earlier pilot in autistic adults. The effect size is striking, but the design is weak: open-label with a waitlist rather than an active placebo, so the result cannot be separated from expectancy. It is a reason to run a proper trial, not yet a reason to believe MDMA treats social anxiety.
Ketamine and the secondary-outcome problem
Ketamine acts within hours and clearly has rapid anxiolytic properties, but its evidence in primary anxiety disorders is thin. Most of the data comes from anxiety measured as a secondary outcome in depression trials, not from dedicated anxiety studies, and the benefit is short-lived without repeated dosing. For anxiety, ketamine is best understood as a fast option for severe or refractory cases rather than an established treatment, and like the others it is not approved for any anxiety disorder.
The expectancy problem, and whether it is really anxiety
Two methodological issues run through all of this. The first is expectancy and unblinding, which is not just a worry but a measured effect: a 2026 meta-analysis found a real but modest anxiety benefit (standardised mean difference of -0.66) and, crucially, that control groups in psychedelic trials improve substantially[10], the signature of strong non-specific effects. The second is conceptual: anxiety and depression travel together, and in several studies the anxiety benefit disappears once depression improvement is accounted for. So a fair reading has to ask, for each result, whether a psychedelic is treating anxiety itself or lifting a low mood that the anxiety was riding on.
Who is developing what
The commercial landscape for primary anxiety is unusually concentrated. MindMed’s MM120 is the only psychedelic with a positive Phase 2b and Breakthrough Therapy designation in generalised anxiety disorder[3], and it is in two Phase 3 trials. Behind it, psilocybin formulations and Cybin’s DMT-analog CYB004 are in earlier generalised-anxiety studies, while a large amount of "anxiety" activity actually sits in cancer and palliative care. A major 2026 review placed anxiety in life-threatening illness among the emerging indications while reserving the strongest evidence for depression and PTSD[11], which is a fair description of where primary anxiety sits: promising, concentrated, and not yet proven.
Reading this honestly
So where do anxiety disorders sit? More cautiously than the volume of coverage implies. Anxiety is the most common mental health condition in the world, but for primary anxiety disorders the psychedelic evidence is thin and rests heavily on a single LSD programme that is still in Phase 3. Psilocybin’s strongest anxiety results are really about end-of-life distress; MDMA’s social-anxiety data is one small open-label trial; ketamine’s anxiety evidence is mostly secondary to depression. None of this means psychedelics will not help with anxiety; the MM120 result is real and the Phase 3 trials are well-designed. It means that, for now, the honest verdict is "promising and unproven", with the next two years of readouts likely to settle which way it goes.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Anxiety Disorders.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| LSD The most advanced psychedelic for primary anxiety. MM120 (LSD) met its Phase 2b endpoint in GAD (a single dose cut Hamilton Anxiety scores by 5 to 6 points more than placebo at the two higher doses), has FDA Breakthrough Therapy status, and is in two Phase 3 trials. But lower doses failed and blinding is a real concern. | Medium | Moderate | Moderate |
| Psilocybin Strong evidence for anxiety in life-threatening illness (see our palliative page), but thin for primary anxiety disorders: dedicated GAD trials are only now recruiting, and most signals are secondary to depression improvement. | Medium | Low | Low |
| MDMA One small open-label, waitlist-controlled trial in social anxiety (n=20) reported a very large effect, plus an earlier pilot in autistic adults. Promising but early, with no active placebo and high expectancy. | Medium | Low | Low |
| Ketamine Rapid but transient anxiolytic effects, mostly measured as a secondary outcome in depression rather than in dedicated anxiety-disorder trials. Used off-label; benefit fades without repeated dosing. | Small | Low | Low |
LSD and Anxiety Disorders
LSD is a long-acting serotonergic psychedelic (a 5-HT2A receptor agonist), and a proprietary form, MindMed’s MM120, is the furthest-along psychedelic for any primary anxiety disorder. In a Phase 2b trial in 198 adults with generalised anxiety disorder, a single dose reduced Hamilton Anxiety scores by 5.0 points (100 µg) and 6.0 points (200 µg) more than placebo at four weeks[1], with benefit reported out to twelve weeks.
On the strength of that result MM120 received FDA Breakthrough Therapy designation and moved into two Phase 3 trials (Voyage and Panorama), reading out in 2026[2]. The honest caveats are built into the same data: the lower 25 µg and 50 µg doses did not separate from placebo, and almost everyone on an active dose noticed perceptual effects, so the Phase 3 programme deliberately includes a design to probe how much of the benefit is expectancy.
Psilocybin and Anxiety Disorders
Psilocybin is a 5-HT2A agonist usually given as a single dose with psychological support. Its strongest anxiety evidence is in people with life-threatening illness: landmark 2016 cancer trials found substantial, sustained reductions in anxiety and depression at six months[1], and a 2025 placebo-controlled trial in palliative patients reported a large drop in state anxiety sustained to 26 weeks[2]. That work is covered on our palliative page, because it targets existential distress rather than a primary anxiety disorder.
For primary anxiety disorders, the picture is much thinner. Dedicated generalised-anxiety trials are only now recruiting, and where anxiety has been measured in other populations it tends to ride on depression: in veterans with treatment-resistant depression, GAD-7 anxiety scores fell 59% but the change was no longer significant after accounting for depression improvement[3]. Psilocybin also shows promise in the anxiety-spectrum condition OCD, where a small randomised trial reported 73% responders and 40% in remission[4], though again the sample was tiny.
MDMA and Anxiety Disorders
MDMA increases serotonin, dopamine and oxytocin signalling and reduces fear responses, which is the rationale for using it in social anxiety, where avoidance of feared social situations is central. The main recent study is a 20-person open-label, waitlist-controlled trial in social anxiety disorder that reported a very large improvement on a standard social-anxiety scale (Hedges’ g of 2.8) with no serious adverse events[1], building on an earlier pilot in autistic adults.
An effect that large should be read cautiously rather than celebrated. The trial was open-label with a waitlist comparison, not an active placebo, so participants knew they had received MDMA, and the design cannot separate the drug from the powerful expectancy that comes with it. It is a genuine early signal in an under-served condition, but it is exactly the kind of result that tends to shrink in later, properly blinded trials.
Ketamine and Anxiety Disorders
Ketamine, an NMDA-receptor antagonist that acts within hours, produces rapid anxiolytic effects and is used off-label for anxiety, often alongside depression. But its evidence in primary anxiety disorders is genuinely thin: most of the data comes from anxiety measured as a secondary outcome in depression trials rather than from dedicated anxiety studies.
The familiar limitation applies here too. The benefit is short-lived, fading within days to weeks unless dosing is repeated, which turns rapid relief into an open-ended maintenance commitment. For anxiety disorders specifically, ketamine is best understood as a fast-acting option for severe or refractory cases, not a demonstrated stand-alone treatment.
Clinical Outlook
The near-term story for primary anxiety hinges almost entirely on LSD. If MM120’s two Phase 3 trials replicate the Phase 2b result[1], a psychedelic could become an approved treatment for generalised anxiety disorder, which would be a landmark for the field and for a condition that has seen little pharmacological innovation in decades. If they do not, much of the current optimism about psychedelics for anxiety will have to be reconsidered, because LSD is carrying most of the weight.
Behind it, psilocybin and DMT-analog programmes are entering controlled generalised-anxiety testing, and MDMA work in social anxiety is early. The honest outlook is cautious optimism narrowly focused on GAD, with most of the rest of the "anxiety" field really belonging either to palliative care or to depression. The next two years of Phase 3 readouts, not the accumulated early-phase enthusiasm, will decide whether psychedelics earn a place in anxiety treatment.
Industrial Landscape
The commercial centre of gravity for primary anxiety is MindMed, whose MM120 (a pharmaceutical form of LSD) is the only psychedelic with a positive Phase 2b and Breakthrough Therapy status in generalised anxiety disorder[1], now in the Voyage and Panorama Phase 3 trials. No other company is as far along in this indication, which makes the field unusually dependent on a single programme.
Behind MindMed, several groups are running earlier generalised-anxiety studies, including psilocybin formulations (oral solution and dose-comparison trials) and Cybin’s DMT-analog CYB004 in GAD with depressive symptoms. These are mostly Phase 2 and earlier. Much of the apparent commercial activity in "anxiety", however, sits in the cancer and palliative space, where developers are testing psilocybin and ketamine for existential distress, work that belongs to our palliative page rather than here.
It is worth being clear about what this concentration means. A field resting on one Phase 3 programme is a field with a single point of failure. A positive MM120 readout would pull the whole area forward; a negative one would leave primary anxiety as one of the least-proven indications in psychedelic medicine, despite being one of the most common conditions in the world.
Quick Indicators
Related Topics
Organisations
Search →OPEN Foundation
Dutch nonprofit organizer in the psychedelic field, including stewardship of the ICPR conference series and related professional convenings.
Cybin
Cybin Inc. (founded 2019) is a Canadian clinical-stage biopharmaceutical company developing psychedelic-based therapeutics—now operating as Helus Pharma—focused on proprietary novel serotonergic agonists and deuterated psilocin analogs for mental health conditions.
Ohio State University
The Ohio State University is a public land-grant research university based in Columbus, Ohio, offering undergraduate, graduate, and professional programs and conducting research across many fields. It was founded as the Ohio Agricultural and Mechanical College and serves as a major educational and economic institution in Ohio.
COMPASS Pathways
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
Diamond Therapeutics
Diamond Therapeutics is a private Canadian clinical-stage company pioneering sub-perceptual (non-hallucinogenic) psilocybin therapy. Their approach focuses on low-dose psilocybin that does not produce psychedelic experiences, enabling at-home outpatient administration — a differentiated strategy from the clinic-based, high-dose psychedelic-assisted therapy model. Founded in 2018 by CEO Judith Blumstock, Diamond completed a Phase 1 single ascending dose study in healthy volunteers (n=56, 7 cohorts, December 2022) establishing a safe non-hallucinogenic dose range. Their Phase 2a GAD programme received Health Canada approval in January 2023 — the first Health Canada NOL for a psychedelic trial in GAD — and enrolled first patients at Kingston Health Sciences Centre in 2025 in the first-ever at-home microdose psilocybin study. A parallel FDA-authorized Phase 2 demoralization trial is also underway at UAB. Diamond is funded by private investors and non-dilutive public grants, including a $1.1M+ CQDM/Brain Canada drug discovery consortium launched in May 2025.
Definium Therapeutics
Definium Therapeutics (formerly Mind Medicine / MindMed) is a late-stage clinical biopharmaceutical company headquartered in New York, founded in 2019 and rebranded in January 2026. Led by CEO Robert Barrow, the company applies scientific rigor to psychedelic-derived molecules to develop accessible, rapidly-acting psychiatric treatments. Its lead asset, DT120 ODT (formerly MM-120) — a pharmaceutically optimised formulation of lysergide D-tartrate (LSD) as an orally disintegrating tablet — has received FDA Breakthrough Therapy Designation for generalised anxiety disorder (GAD) and delivered compelling Phase 2b results: 65% clinical response rate and 48% remission at 12 weeks following a single dose. Three Phase 3 trials are currently underway: Voyage and Panorama (GAD) and Emerge (MDD, fully enrolled). Topline data from all three studies is expected in 2026, potentially positioning Definium for the first-ever FDA approval of an LSD-derived therapy. A second pipeline asset, DT402 (formerly MM402) — an MDMA-related compound — is in Phase 1 development for autism spectrum disorder.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
Resilient Pharmaceuticals
Resilient Pharmaceuticals (formerly Lykos Therapeutics, formerly MAPS PBC) is a US-based public benefit corporation developing MDMA-assisted therapy for PTSD. It was founded in 2014 by MAPS as a commercial spinout to carry MAPS MDMA research through late-stage trials and regulatory approval. After two Phase 3 trials and an NDA filing, FDA issued a Complete Response Letter in August 2024 and requested an additional Phase 3 trial before approval. The company subsequently restructured and rebranded, while the public Lykos web presence continues to describe the organisation as pursuing FDA approval for MDMA-assisted therapy. As of the June 2026 review, no public company announcement of a new pivotal trial start or NDA resubmission date was found. VA/DoD-backed MDMA/PTSD research is proceeding in the broader field, but it should not be treated as direct support for Resilient/Lykos NDA resubmission unless linked by company or FDA evidence.
MAPS
MAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Ketamine Research Institute
The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.
Portland Psychotherapy
Portland Psychotherapy is a Portland, Oregon clinic, research, and training center that integrates psychedelic science into evidence-based clinical practice, conducting clinical trials of MDMA-assisted therapy for social anxiety disorder and offering psychedelic integration services. Their distinctive model funds peer-reviewed research through clinical revenue, resulting in exceptionally well-trained therapists in psychedelic-assisted care.
People
Search →Federico Cavanna
Researcher in psychedelic science / neuroscientific researcher (exact current title not confidently verified)
He is a coauthor on multiple widely cited studies on psilocybin microdosing, DMT, and psychedelic use, helping characterize subjective, behavioral, and cognitive effects of psychedelics.
Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Eduardo Schenberg
Neuroscientist and founder/director of Instituto Phaneros
A leading Brazilian psychedelic researcher known for clinical and translational work on ayahuasca, ibogaine, MDMA, and ethics/policy in psychedelic medicine.
Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Aaron Klaiber
Doctoral researcher at the University of Basel
He appears as an author on multiple controlled human psychedelic studies spanning DMT, mescaline, MDMA, LSD, and psilocybin, suggesting a substantial role in contemporary psychopharmacology research.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Juliana Rocha
Doutoranda em Ciências Médicas / Saúde Mental at the Ribeirão Preto Medical School, University of São Paulo
She is a recurring coauthor on clinical psychedelic studies, especially ayahuasca trials on social anxiety, emotion recognition, personality, and social cognition, helping expand the human evidence base for psychedelic-assisted psychiatric research.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Connected Evidence
The latest clinical data and verified academic findings associated with Anxiety Disorders.